

Durable remissions in *TCF3-HLF* positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation

Brice Mouttet,¹ Luciana Vinti,² Philip Ancliff,³ Nicole Bodmer,¹ Benoît Brethon,⁴ Gunnar Cario,⁵ Christiane Chen-Santel,⁶ Sarah Elitzur,⁷ Volkan Hazar,⁸ Joachim Kunz,⁹ Anja Möricke,⁵ Jerry Stein,¹⁰ Ajay Vora,³ Yöntem Yaman,⁸ Martin Schrappe,^{5,11} Sema Anak,⁸ André Baruchel,⁴ Franco Locatelli,² Arend von Stackelberg,⁶ Martin Stanulla¹² and Jean-Pierre Bourquin¹

¹Pediatric Oncology, University Children's Hospital Zurich, Switzerland; ²Department of Pediatric Haemato-Oncology, IRCCS Ospedale Bambino Gesù, Sapienza University of Rome, Italy; ³Haematology and Oncology Department, Great Ormond Street Hospital, London, UK; ⁴Department of Pediatric Hematology, Hôpital Robert Debré, Assistance Publique – Hôpitaux de Paris, France; ⁵Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany; ⁶Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin, Berlin, Germany; ⁷Pediatric Hematology-Oncology, Schneider Children's Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel; ⁸Department of Pediatric Hematology, Medipol University Hospital, Istanbul, Turkey; ⁹Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Germany; ¹⁰Bone Marrow Transplant Unit, Schneider Children's Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel; ¹¹Pediatrics, Christian Albrechts University Kiel, University Medical Center, Kiel, Germany and ¹²Pediatric Hematology and Oncology, Hannover Medical School, Germany

Correspondence: JEAN-PIERRE BOURQUIN.
jean-pierre.bourquin@kispi.uzh.ch
doi:10.3324/haematol.2018.210104

Supplemental Table 1: Quantitative and Sensitivity Ranges of MRD markers, GvHD classification and additional clinical information.

No.	Quantitative Range			Sensitivity Range			GvHD classification	RIALTO	Molecular Diagnostic	Last MRD date (days post blina)	Blinatumomab Dosage (m ² d)				CD19 status at relapse	Cytogenetics at relapse
	Marker 1	Marker 2	Marker 3	Marker 1	Marker 2	Marker 3					Cycle 1	Cycle 2	Cycle 3	Cycle 4		
Patient 1	5x 10 ⁻⁴	5x 10 ⁻⁴	5x 10 ⁻⁴	1x 10 ⁻⁴	1x 10 ⁻⁴	1x 10 ⁻⁴	chronic	Yes	FISH	91	d1-d7: 5 µg, then 15 µg	5 µg	–	–	–	–
Patient 2	1x 10 ⁻⁴	1x 10 ⁻⁴	–	1x 10 ⁻⁴	1x 10 ⁻⁴	–	acute	Yes	FISH	1292	d1-d7: 5 µg, then 15 µg	15 µg	15 µg	–	–	–
Patient 3	1x 10 ⁻³	5x 10 ⁻⁴	–	5x 10 ⁻⁴	1x 10 ⁻⁵	–	chronic	–	FISH (Cytocell)	489	15 µg	15 µg	7.5 µg	15 µg	–	–
Patient 4	1x 10 ⁻⁴	1x 10 ⁻⁴	–	1x 10 ⁻⁴	1x 10 ⁻⁵	–	–	–	FISH (Cytocell)	–	15 µg	15 µg	15 µg	–	positive	unchanged
Patient 5	1x 10 ⁻⁴	–	–	1x 10 ⁻⁵	–	–	–	–	RT-PCR	–	15 µg	15 µg	15 µg	–	negative	not performed
Patient 6	1x 10 ⁻⁴	1x 10 ⁻⁴	–	1x 10 ⁻⁵	1x 10 ⁻⁵	–	acute	–	RT-PCR and FISH	–	15 µg	–	–	–	positive	unchanged
Patient 7	1x 10 ⁻⁴	1x 10 ⁻⁴	–	1x 10 ⁻⁵	1x 10 ⁻⁵	–	–	–	RT-PCR ¹	300	15 µg	15 µg	–	–	–	–
Patient 8	1x 10 ⁻⁴	1x 10 ⁻⁴	–	1x 10 ⁻⁴	1x 10 ⁻⁴	–	–	–	FISH (Cytocell)	50	15 µg	15 µg	–	–	–	–
Patient 9	1x 10 ⁻⁴	5x 10 ⁻⁴	–	1x 10 ⁻⁵	1x 10 ⁻⁴	–	–	–	RT-PCR ¹	71	15 µg	15 µg	–	–	–	–

RIALTO, Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL (NCT02187354)

1: RT-PCR reference: van der Velden VH, et al. Leukemia. 2007 Apr;21(4):706-13